Federal judge orders Fulton County Georgia election case documents unsealed by Tuesday Prediction: The Trump bull market will come to an abrupt end from an unlikely source -- the Federal Reserve Who ...

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors. Under current NCCN guidelines as of mid-December 2025, ...

Antibody drug conjugates (ADCs) mark a new era in targeted cancer therapy, delivering potent cytotoxic chemotherapy via monoclonal antibodies directly into the tumor cells — an era with potentially ...

ClickFix attacks have evolved to feature videos that guide victims through the self-infection process, a timer to pressure targets into taking risky actions, and automatic detection of the operating ...

Explore how digital feedback controllers manage motors, pressure, temperature, and more, and learn why ADC and DAC performance are crucial when designing robust embedded systems. How to define the ...

Paclitaxel, ifosfamide, cisplatin (TIP) in patients with advanced urethral adenocarcinoma: A single center, retrospective analysis. Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Application security firm F5 Inc. today laid out a new framework for the evolution of application delivery controllers aimed at addressing the increasing complexity of hybrid, multicloud and ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another product ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...